Media coverage about Amgen (NASDAQ:AMGN) has been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amgen earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 46.589667297518 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- AMGN Named ‘Top Dividend Stock of the Nasdaq 100’ at Dividend … – Nasdaq (nasdaq.com)
- Head to Head Contrast: Amgen (AMGN) versus Its Rivals (americanbankingnews.com)
- Is the Stock In Play?: Amgen Inc (NASDAQ: AMGN) – Alpha Beta Stock (alphabetastock.com)
- Japan’s Kirin cashes out of Amgen drug joint venture – Reuters – Reuters (reuters.com)
- Amgen to pay Kirin $780M for ownership of joint venture (seekingalpha.com)
A number of equities analysts have recently commented on AMGN shares. Mizuho restated a “buy” rating and set a $195.00 price objective on shares of Amgen in a research note on Sunday, July 9th. ValuEngine upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Jefferies Group LLC restated a “buy” rating and set a $195.00 price objective on shares of Amgen in a research note on Tuesday, July 11th. Cann restated a “buy” rating and set a $203.00 price objective (up from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. Finally, Argus increased their price objective on shares of Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Twelve equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $190.03.
Amgen (AMGN) opened at 175.22 on Wednesday. The firm has a 50-day moving average of $184.39 and a 200 day moving average of $172.38. The company has a market capitalization of $127.85 billion, a PE ratio of 15.96 and a beta of 1.36. Amgen has a 12-month low of $133.64 and a 12-month high of $191.10.
Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The company’s quarterly revenue was down .7% on a year-over-year basis. During the same period in the previous year, the company earned $3.02 earnings per share. Analysts forecast that Amgen will post $12.66 EPS for the current fiscal year.
Amgen declared that its board has authorized a share buyback plan on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be paid a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a yield of 2.63%. The ex-dividend date of this dividend is Thursday, November 16th. Amgen’s payout ratio is 41.63%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.19% of the stock is owned by insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
What are top analysts saying about Amgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen Inc. and related companies.